Eysuvis™ (loteprednol etabonate) – New drug approval
October 27, 2020 - Kala Pharmaceuticals announced the FDA approval of Eysuvis (loteprednol etabonate) 0.25% ophthalmic suspension, for the short-term (up to two weeks) treatment of the signs and symptoms of dry eye disease.
Download PDF
